Ceryvyn Therapeutics Limited

OTCPK:OPTE.Y Stock Report

Market Cap: US$13.3m

Ceryvyn Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Ceryvyn Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-3.0%

Buyback Yield

Total Shareholder Yield-3.0%
Future Dividend Yield0%
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Seeking Alpha • Jan 30

Opthea: Small Australian Company Aiming To Upend The Wet AMD Market

Summary Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD, showing promising Phase 2b results. Wet AMD treatments like Lucentis and Eylea have limitations; sozinibercept aims to improve efficacy by targeting a broader VEGF family. Financially, Opthea has a market cap of $797mn and a cash runway of 4-5 quarters, but faces transparency and dilution risks. Despite compelling data, market entry challenges and low trading volume make me cautious; I await topline data before investing. Read the full article on Seeking Alpha
Seeking Alpha • Nov 07

Opthea Limited: Major Catalyst In Early 2025 For Complementary Eye Disease Candidate

Summary Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 results due in 2025. The wet AMD market is lucrative, but the challenge lies in the patient's willingness to receive two intravitreal injections for potentially better outcomes. Phase 2b results were promising, but Phase 3 studies face uncertainties due to different standards of care and longer study durations, amongst other reasons. Opthea's financial pressure and competitive landscape make it a risky investment; I assign a "Hold" rating pending Phase 3 outcomes. Read the full article on Seeking Alpha
Seeking Alpha • Aug 30

Opthea GAAP EPS of -$0.26 misses by $0.03

Opthea press release (NASDAQ:OPT): FY GAAP EPS of -$0.26 misses by $0.03. As of June 30, 2022, Opthea had cash, cash equivalents and short-term investments of $44.6 million.
Seeking Alpha • Aug 15

Opthea receives $170M in non-dilutive financing for OPT-302 in wet AMD

Opthea (NASDAQ:OPT) entered into a non-dilutive financing transaction for up to $170M from investment funds working with Launch Therapeutics to finance and advance the ongoing Phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related macular degeneration. Launch Tx is the recently formed development company backed by funds managed by global investment firm Carlyle and its life sciences franchise, Abingworth. Under agreement terms, the funds managed by Carlyle and Abingworth, in collaboration with Launch Tx, will commit $120M in three installments at fixed time points and retain an option to commit another $50M. Opthea retains full worldwide commercial rights for OPT-302 and has the option to prepay its obligations in full at any time. "This strategic transaction is expected to fund us through Phase 3 topline data expected in mid-2024 and strengthens our strategic position to maximize the value of OPT-30," CEO Dr Megan Baldwin commented.

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if OPTE.Y's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OPTE.Y's dividend payments have been increasing.

Dividend Yield vs Market

Ceryvyn Therapeutics Dividend Yield vs Market
How does OPTE.Y dividend yield compare to the market?
SegmentDividend Yield
Company (OPTE.Y)n/a
Market Bottom 25% (US)1.3%
Market Top 25% (US)4.2%
Industry Average (Biotechs)2.3%
Analyst forecast (OPTE.Y) (up to 3 years)0%

Notable Dividend: Unable to evaluate OPTE.Y's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OPTE.Y's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate OPTE.Y's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as OPTE.Y has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 15:59
End of Day Share Price 2026/07/07 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ceryvyn Therapeutics Limited is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Elyse ShapiroCanaccord Genuity
John SavinEdison Investment Research
Chris CooperGoldman Sachs